78449
document
Metabolic and circulatory effects of oral salbutamol in the third trimester of pregnancy in diabetic and non-diabetic women . Metabolic and cardiovascular effects of 4 mg oral salbutamol were studied in ten non-diabetic , ten chemical diabetic and five juvenile diabetic women in late pregnancy . None of the women had been treated with beta-sympathomimetic drugs earlier in their pregnancy . Heart rate and blood pressure were recorded and blood samples for measurement of plasma cyclic AMP , insulin , C-peptide , glucose , lactate , glycerol , non-esterified fatty acids ( NEFA ) and 3-hydroxybutyrate ( 3-HB ) were collected every 30 minutes for 120 minutes after salbutamol . All women underwent the same procedure at random without salbutamol . There were significant cardiovascular effects of salbutamol in all the groups but no differences in these effects between the groups . Salbutamol caused significant increases of glycogenolysis and lipolysis in all the groups , significantly larger in the juvenile diabetic than the non-diabetic and chemical diabetic women . This observation could be explained by the inability of the juvenile diabetics to secrete insulin , shown by their non-measureable plasma C-peptide levels . The metabolic responses following salbutamol in the chemical diabetics were intermediate between the non-diabetic and juvenile diabetic groups . The results show that diabetes does not alter the sensitivity of beta-receptors involved in cardiovascular regulation , while the metabolic responses to oral salbutamol are enhanced , especially in juvenile diabetics . We suggest that during treatment with beta-sympathomimetic drugs , blood glucose should be monitored in all patients showing criteria of potential diabetes .
78450
Intervention_Pharmacological
salbutamol
78451
Intervention_Pharmacological
4 mg oral salbutamol
78452
Intervention_Pharmacological
beta-sympathomimetic drugs
78453
Intervention_Pharmacological
salbutamol
78454
Intervention_Pharmacological
underwent the same procedure at random without salbutamol
78455
Intervention_Pharmacological
salbutamol
78456
Intervention_Pharmacological
Salbutamol
78457
Intervention_Pharmacological
salbutamol
78458
Intervention_Pharmacological
salbutamol
78459
Intervention_Pharmacological
beta-sympathomimetic drugs
78460
Outcome_Physical
Metabolic and cardiovascular effects
78461
Outcome_Physical
Heart rate
78462
Outcome_Physical
blood pressure
78463
Outcome_Physical
blood samples for measurement of plasma cyclic AMP , insulin , C-peptide , glucose , lactate , glycerol , non-esterified fatty acids ( NEFA ) and 3-hydroxybutyrate ( 3-HB )
78464
Outcome_Physical
cardiovascular effects
78465
Outcome_Physical
glycogenolysis and lipolysis
78466
Outcome_Physical
metabolic responses
78467
Participant_Condition
diabetic
78468
Participant_Condition
non-diabetic
78469
Participant_Sex
women .
78470
Participant_Sample-size
ten
78471
Participant_Condition
non-diabetic
78472
Participant_Sample-size
ten
78473
Participant_Condition
chemical diabetic
78474
Participant_Sample-size
five
78475
Participant_Condition
juvenile diabetic
78476
Participant_Sex
women
78477
Participant_Sex
women
78478
Participant_Condition
juvenile diabetic
78479
Participant_Condition
non-diabetic
78480
Participant_Condition
chemical diabetic
78481
Participant_Sex
women
78482
Participant_Condition
diabetes